Navigation Links
Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:2/10/2011

About Optimer Pharmaceuticals, Inc.Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the proposed public offering of securities by Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to market conditions and the satisfactio
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
2. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
3. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
4. Optimer Pharmaceuticals Announces Key Additions to Management Team
5. Optimer Pharmaceuticals Obtains Additional Fidaxomicin Patent
6. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
7. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
8. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
11. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SHENZHEN, China, Nov. 26, 2014 China Nepstar ... the "Company"), a leading retail drugstore chain in China ... announced its unaudited financial results for the third quarter ... ended September 30, 2014: , Same store sales increased ... , Revenue increased by 8.1% to RMB738.3 million (US$120.3 ...
(Date:11/24/2014)... , Nov. 24, 2014 Luoxis Diagnostics, ... MKT: AMPE), today announced the presentation of three ... System as a broadly applicable and robust research ... the body in response to injury, illness, or ... in collaboration with Luoxis, academic and pharmaceutical research ...
(Date:11/24/2014)... CLEVELAND , Nov. 24, 2014  Surgical Theater, ... at the November 24 th opening of ... IRCCS Istituto Neurologico Nazionale "C. Besta." The SuRgical Planner ... be showcased at the event for their 3D navigation ... Dr. Joshua Bederson , Professor and Chair, Department ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 2Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 3Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 4Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress 5Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3
... 20, 2011 Robbins & Myers, Inc. (NYSE: ... first quarter fiscal 2012 ending November 30, 2011 before the ... 9:00 a.m., CT / 10:00 a.m., ET on January 6.  ... J. Brown, Interim Chief Financial Officer & Corporate Controller, will ...
... HACKENSACK, N.J., Dec. 20, 2011 In an ... error rates, HackensackUMC recently announced the implementation of ... SurgiCount Safety-Sponge®  is a product of SurgiCount Medical, ... Technologies, Inc. (OTCBB:PSTX, OTCQB:PSTX). This system provides a ...
Cached Medicine Technology:HackensackUMC Adopts SurgiCount Safety-Sponge® System 2HackensackUMC Adopts SurgiCount Safety-Sponge® System 3
(Date:11/26/2014)... HILLS, CA (PRWEB) November 26, 2014 With ... costing thousands of dollars, the prosthodontists at the Anacapa Dental ... paying for dental procedures can be daunting for some. , ... pay for the procedures they offer. , “No dentist wants ... and beautiful set of teeth,” said Dr. Mamaly Reshad, partner ...
(Date:11/26/2014)... 26, 2014 ISI Telemanagement Solutions, ... has been award the 2014 Lync Pioneer ... award comes as a great honor to ISI, ... Lync ecosystem. Specifically, ISI offers an integrated collaboration ... Lync communication, including voice, video, Lync IM, and ...
(Date:11/26/2014)... 26, 2014 Bunion Bootie, the newest ... in an early celebration of the early holiday shopping ... offered at the promotional price of $29.95 each (normally ... addition to any automatic discounts applied when buying more ... website for complete details. It’s simple: purchasing more ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. Hill, ... from The American Association of Nurse Practitioners ... nurse practitioners. The Distinguished Preceptorship Award recognizes the ... significant contribution toward increasing the awareness and acceptance ... (AANP) is the largest full-service national professional membership ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:ISI Telemanagement Solutions, Inc. has been Awarded the 2014 Microsoft Lync Pioneer Award 2Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... Doctors more often tell younger people to change diet, get ... -- Americans over 60 with high blood pressure are less ... on how lifestyle changes can lower their blood pressure, a ... North Carolina at Chapel Hill analyzed data from a U.S. ...
... Shengtai,Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical",or ... high-quality,pharmaceutical grade glucose products in China, today reported ... 2007. First Quarter of Fiscal 2008 Highlights ... $19.4 million -- Gross profit rose ...
... PORTLAND, Ore., Nov. 15 Every year more,holiday ... will stand,out above the rest while helping families ... organization, has taken this,charitable holiday gift-giving approach to ... http://www.mercycorps.org . Mercy Kits give people ...
... Va., Nov. 15 With the holidays,quickly approaching, ... As decorations go up, extension cords will be ... The Electrical Safety Foundation,International (ESFI) urges you to ... improper use can pose serious shock and fire ...
... Approved for Retreating Both Hepatitis ... C Relapsers and Nonresponders, ... today announced that the European Commission on,October 30 approved 48-week ... (ribavirin, 800 - 1,400 mg,daily) combination therapy for retreating adult ...
... life is one key factor to avoiding a number of ... University of Arizona and the University of Wisconsin, Madison, indicates ... have a strong relationship are more likely to delay the ... in the Norton School of Family and Consumer Sciences at ...
Cached Medicine News:Health News:Older Hypertension Patients Less Likely to Get Lifestyle Advice 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008 11Health News:Online Charitable Holiday Giving: Making a Difference with the Gifts You Give 2Health News:Holiday Decorating and Extension Cords 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Girls will be girls longer when home life is stable 2
... The VASER System represents a ... ultrasonic technology to cosmetic procedures. Combined ... selective tissue emulsification, a solid grooved ... the VASER System has been designed ...
... The next generation of the ... PSI-TEC III retains all the ... PSI-TEC a leading name for,aspiration ... flow,vacuum pumps for high powered ...
Richardson Retractor...
Our most popular saline breast implant style for over 20 years. A full, rounded look that adds greater dimension to the breast....
Medicine Products: